(30 days)
The Ultra Mirage II Mask is intended for multipatient re-use for adult patients prescribed continuous positive airway pressure (CPAP) or bilevel therapy in hospitals, clinic and home environments.
The Ultra Mirage II Mask is designed for adult patients for the delivery of non-invasive ventilatory support using continuous positive airway pressure or bi-level therapy. It is intended for multiplepatient re-use and is minimally obtrusive to the user, providing a high level of comfort, ease-of-use and seal. The Ultra Mirage II Mask is a nasal mask supported by headgear to allow a seal with the patients face. The Ultra Mirage II Mask may then be connected via tubing to a CPAP or bi-level flow generator. Ventilation is applied to the lungs in a non-invasive manner. The Ultra Mirage II Mask comes in one frame size with four cushion variants (standard, large, shallow, shallow-wide).
The provided text describes a 510(k) premarket notification for the "Ultra Mirage II Mask," a device for delivering non-invasive ventilatory support. The key focus of the submission is to demonstrate substantial equivalence to legally marketed predicate devices, rather than defining and proving specific acceptance criteria in the manner one might find for a novel AI/software device.
Therefore, the information requested, which is typically relevant for studies validating AI models against specific performance metrics (like sensitivity, specificity, or AUC), is largely not applicable or not present in this document.
However, I can extract the relevant information regarding the equivalence study and any performance details.
Here's a breakdown of the available information structured as requested, with "N/A" where the information is not provided or applicable to this type of medical device submission:
Acceptance Criteria and Device Performance for Ultra Mirage II Mask
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (Implied) | Reported Device Performance |
|---|---|
| Safety: Biocompatibility | Materials tested to ISO 10993 standards by an independent certified laboratory. Details referenced in section 5.4 (not provided in excerpt). |
| Effectiveness: Substantial Equivalence to Predicate Devices (Modular Mask K961783 & Mirage Activa K032916) | "Performance testing has been carried out to verify the safety and effectiveness of the Ultra Mirage II Mask." "The results of the performance data show that the Ultra Mirage II mask is substantially equivalent to the Modular (K961783) and Mirage Activa (K032916) predicate masks (refer section 5.2.1)." The document asserts equivalence to ResMed's Ultra Mirage Mask fittings for Autoset Spirit (K013843) and S7 Elite (K013909). |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size: Not specified. The submission refers to "performance testing" but does not detail the number of subjects or tests conducted.
- Data Provenance: Not specified, but generally, such testing for physical medical devices would involve laboratory tests and potentially user trials. Not explicitly prospective or retrospective.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications
- N/A. This type of device (a mask) does not typically involve expert-established ground truth in the way an AI diagnostic algorithm would. The "ground truth" for performance would likely be engineering specifications, physical measurements, and clinical usability assessments.
4. Adjudication Method for the Test Set
- N/A. Not applicable to the performance testing described for this device.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
- No. This is not an AI/software device, and therefore an MRMC study comparing human readers with and without AI assistance is not relevant.
6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done
- N/A. This is a physical medical device, not an algorithm.
7. The Type of Ground Truth Used
- For Safety: Compliance with ISO 10993 standards for materials biocompatibility.
- For Effectiveness: Direct comparison of technological characteristics and performance (e.g., seal, comfort, ease of use, ventilatory support delivery) to defined predicate devices, with the goal of demonstrating "substantial equivalence." The specific metrics of this comparison are not detailed in the provided text.
8. The Sample Size for the Training Set
- N/A. This is not an AI/machine learning device that uses a "training set."
9. How the Ground Truth for the Training Set Was Established
- N/A. Not applicable.
Summary of the Study that Proves the Device Meets Acceptance Criteria:
The provided document highlights a performance testing study designed to demonstrate the "substantial equivalence" of the Ultra Mirage II Mask to existing predicate devices (Modular Mask K961783 and Mirage Activa K032916).
- Proof of Safety: The biocompatibility of materials used in skin-contacting and air-path components was verified through testing to ISO 10993 standards by an independent certified laboratory.
- Proof of Effectiveness/Equivalence: General "performance testing" was conducted to confirm that the Ultra Mirage II Mask is substantially equivalent in its fundamental scientific technology to the predicate devices. The document states that the results of this testing supported the claim of substantial equivalence. While specific performance metrics or detailed test results are not included in this summary, the FDA's clearance (K050359) indicates they review this data and found it sufficient for the claim of substantial equivalence. The design is explicitly stated as being "with a minimal number of design changes" from the original Ultra Mirage Mask, further emphasizing the equivalence approach. The submission also refers to the Ultra Mirage II Mask's equivalence to existing ResMed mask fittings for Autoset Spirit (K013843) and S7 Elite (K013909), suggesting consistency with established product lines.
{0}------------------------------------------------
MAR 16 2005
Sponsor:
ResMed Ltd
510(K) SUMMARY ﺑﻴﺮ
510(k) SUMMARY—Ultra Mirage II Mask
| Submitter Name: | ResMed Corp. |
|---|---|
| Submitter Address: | 14040 Danielson Street, Poway CA 92064-6857USA |
| Contact Person: | David D'Cruz, VP US Clinical & Regulatory Affairs |
| Phone Number: | (858) 746 2238 |
| Fax Number: | (858) 746 2915 |
| Date Prepared: | February 11, 2005 |
| Device Trade Name: | Ultra Mirage II Mask |
| Device Common NamelClassification Name: | Ultra Mirage II Mask |
| Predicate Devices: | K961783 Modular MaskK032916 Mirage Activa |
Device Description:
The Ultra Mirage II Mask is designed for adult patients for the delivery of non-invasive ventilatory support using continuous positive airway pressure or bi-level therapy. It is intended for multiplepatient re-use and is minimally obtrusive to the user, providing a high level of comfort, ease-of-use and seal.
Intended Use:
The Ultra Mirage II Mask is intended for multipatient re-use for adult patients prescribed continuous positive airway pressure (CPAP) or bilevel therapy in hospitals, clinic and home environments.
{1}------------------------------------------------
Device Technological Characteristics and Comparison to Predicate Device(s):
Overview:
Overview :
The Ultra Mirage II Mask is a nasal mask supported by headgear to allow a seal with the patients The Ottra Mirage II Mask may then be connected via tubing to a CPAP or bi-level flow lace. The Olira Mirage in Made mayentilation is applied to the lungs in a non-invasive manner.
The Ultra Mirage II Mask comes in one frame size with four cushion variants (standard, large, shallow, shallow-wide).
The Ultra Mirage II Mask design is substantially equivalent to predicate devices. The Ultra Mirage I he Otta Mirage in mask dolgh to educal and has the same fundamental scientific technology as its predicates.
Performance Data:
r efformance testing has been carried out to verify the safety and effectiveness of the Ultra Mirage r enominer tooling noo boon carnoe is equivalent to ResMed's Ultra Mirage Mask as ir Mask. THO Olira Mirago It fitten Autoset Spirit (K013843) and S7 Elite (K013909) submissions. The results of the performance data show that the Ultra Mirage II mask is substantially equivalent to the Modular (K961783) and Mirage Activa (K032916) predicate masks (refer section 5.2.1)
Materials Biocompatibility
Materials have been carefully selected to ensure patient safety and efficacy of the product. Those materials used to create components of the Ultra Mirage II Mask, which contact the skin and/or the air-path, have been tested to the ISO 10993 standards by an independent certified laboratory. The details are referenced in section 5.4.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines representing its body and wings. The logo is surrounded by text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
Public Health Service
MAR 16 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
ResMed Limited C/O Mr. David D' Cruz Vice President US Clinical & Regulatory Affairs ResMed Corporation 14040 Danielson Street Poway, California 92064-6857
Re: K050359
Trade/Device Name: Ultra Mirage II Mask Regulation Number: 868.5905 Regulation Name: Noncontinuous Ventilator (IPPB) Regulatory Class: II Product Code: BZD Dated: February 11, 2005 Received: February 14, 2005
Dear Mr. D'Cruz:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device micrsate comments, or to devices that have been reclassified in accordance with the provisions of Amendinens, or to do roses ken metic Act (Act) that do not require approval of a premarket the Federal F USA). You may, therefore, market the device, subject to the general approvisions of the Act. The general controls provisions of the Act include controls provisions of a listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting (1 MA), it may be subject to fact of Federal Regulations, Title 21, Parts 800 to 898. In your device ear oe founcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2 - Mr. D'Cruz
Please be advised that FDA's issuance of a substantial equivalence determination does not I Trase oc advisour that 122 a determination that your device complies with other requirements mean that I Dr may Federal statutes and regulations administered by other Federal agencies. of the Act of any t oderal banks and surfection to be not limited to: registration r ou must comply with a 807); labeling (21 CFR Part 801); good manufacturing practice allu listing (21 CF ref art 087), abouting systems (QS) regulation (21 CFR Part 820); and if requirements us bet form in are quadiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) This letter will around Jo The FDA finding of substantial equivalence of your device to a premaired predicated. - I a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), 11 you desire specific acroof Compliance at (240) 276-0120. Also, please note the regulation entitled "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the may ovent of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Chiu Lin, Ph.D.
Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
INDICATIONS FOR USE র্ব
510(k) Number (if known): KoSO359
Ultra Mirage II Mask Device Name: _________________________________________________________________________________________________________________________________________________________________
Indications For Use:
The Ultra Mirage II Mask is intended for multipatient re-use for adult patients prescribed The other winess in Mast pressure (CPAP) or bilevel therapy in hospitals, clinic and home environments.
Prescription Use × (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Que Suliom
mon Sign-Off) ം. colon Control. Dental De
Page 1 of ____________________________________________________________________________________________________________________________________________________________________
) Number K050359
§ 868.5905 Noncontinuous ventilator (IPPB).
(a)
Identification. A noncontinuous ventilator (intermittent positive pressure breathing-IPPB) is a device intended to deliver intermittently an aerosol to a patient's lungs or to assist a patient's breathing.(b)
Classification. Class II (performance standards).